In a recent update, Takeda touted its plans for a dozen new molecular entities that could potentially generate 14 approvals and over $10 billion in potential sales. The NMEs are part of a first wave that will target cancer, gastroenterology, neuroscience, rare diseases and vaccines, and will be followed by another wave of treatments using new platforms, such as cell and gene therapies, as well as novel mechanisms.
Takeda unveils details on 12 new molecular entities worth billions
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.